The DDD-monitoring of consumption of fluoroquinolones when treating community-acquired pneumonia in a multi-specialty hospital in the Republic of Tajikistan

Abstract

Community-acquired pneumonia is one of the most common diseases and is still the leading cause of death among infectious diseases. Such drugs as β-lactam antibiotics, new macrolides (azithromycin, clarithromycin) and respiratory fluoroquinolones are of the greatest importance in the treatment of community-acquired pneumonia in adult patients worldwide.Aim. To analyze and assess the dynamics of consumption of fluoroquinolones for the treatment of community-acquired pneumonia in a multi-specialty hospital in the Republic of Tajikistan using the DDD-methodology.Materials and methods. A retrospective descriptive analysis of medical prescriptions for pharmacotherapy of patients treated in the Pulmonology department of the Sogdigh Regional Clinical Hospital (Khujand, Republic of Tajikistan) was performed. The consumption of fluoroquinolones was estimated according to the ATC/DDD index of the WHO. The unit of measurement used was the number of grams of the active substance with further calculation of the DDD/100 bed-days and % of the total DDD.Results and discussion. The DDD analysis of consumption of fluoroquinolones in the Pulmonology department of the multi-specialty hospital showed a significant change in the structure of consumption of this group of drugs for the initial antibiotic therapy of community-acquired pneumonia in the last five years. A clear tendency was observed to reduce the consumption of this class of drugs in 2011-2015. There is a significant reduction in the consumption of ofloxacin and levofloxacin against the background of a slight tendency to increase the demand for ciprofloxacin in the treatment of pneumonia in the inpatient drug treatment.Conclusions. Monitoring of the consumption of antimicrobial drugs from the fluoroquinolone group for the treatment of community-acquired pneumonia in the Pulmonology department of the multi-specialty hospital using the ATS/DDD-methodology makes it possible to assess the tactics of community-acquired pneumonia treatment in this region, its compliance with the international standards and the risks of developing the drug-resistant microflora, in particular to fluoroquinolones.